New anti-hepatitis B virus drugs under development and evaluation
Explore this paper's citation graph
Summary
The state-of-the-art for anti-HBV drugs is summarized and several novel therapies are promising in early clinical trials and combination of newly developing and current antiviral drugs may cure CHB in the clinic.
- Type
- review
- Published
- 2016-09-26
- Cited by
- 4
- References
- 74
- OpenAlex
- https://openalex.org/W2523927750
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:32851143
Keywords
Medicine, Hepatitis B virus, Viral replication, Drug development, Immune system
References
- Chronic hepatitis B: a wave of new therapies on the horizon
- Two distinct types of hepatitis in experimental hepatitis B virus infection.
- Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities.
- NTCP opens the door for hepatitis B virus infection.
- Progress and Prospects of Anti-HBV Gene Therapy Development
- Early events in hepatitis B virus infection: From the cell surface to the nucleus
- LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours
- HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B
- A systematic analysis of the predicted human La protein targets identified a hepatitis B virus infection signature
- Present and Future Therapies of Hepatitis B: From Discovery to Cure
- Application of CRISPR/Cas9 Technology to HBV
- Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses
- Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection
- A Novel Inhibitor of Human La Protein with Anti-HBV Activity Discovered by Structure-Based Virtual Screening and In Vitro Evaluation
- The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
- Current developments in nucleoside/nucleotide analogues for hepatitis B
- Inhibitors of Hepatitis B Virus Attachment and Entry
- The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.
- Sustained Efficacy and Seroconversion with the Toll-Like Receptor 7 Agonist GS-9620 in the Woodchuck Model of Chronic Hepatitis B
- Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs.
Cited by
- New antivirals for the treatment of chronic hepatitis B
- Alteration of microRNA profiles by a novel inhibitor of human La protein in HBV‐transformed human hepatoma cells
- Study on the structure optimization and anti‐hepatitis B virus activity of novel human La protein inhibitor HBSC11
- A two-step lineage reprogramming strategy to generate functionally competent human hepatocytes from fibroblasts
Related papers
- People's Drug Guide to Deadly Drug Interactions Focuses on Drug/Drug, Drug/Food, and Drug/Vitamin Interactions:
- Me-too drug,me-better drug and me-new drug in drug R&D
- The People's Guide to Deadly Drug Interactions: How to Protect Yourself from Life-Threatening Drug/Drug, Drug/Food, Drug/Vitamin Combinations
- [Drug-drug interactions in diabetic patients at the Department of Clinical Pharmacology].
- Prevalence of hepatitis B virus infection in the Gezira state of central Sudan.
- Detection of Hepatitis B virus Markers in 587 Medical Workers